141 related articles for article (PubMed ID: 38828476)
1. Achieving Durable Forehead Line Outcomes With DaxibotulinumtoxinA: Early Experience in Real-World Clinical Practice.
Lafkas M
Aesthet Surg J Open Forum; 2024; 6():ojae023. PubMed ID: 38828476
[TBL] [Abstract][Full Text] [Related]
2. Impact of DaxibotulinumtoxinA for Injection on Brow Position and Frontalis Muscle Activity Following Treatment of Glabellar Lines.
Solish N; Kane MAC; Biesman BS; Brown J; Gallagher CJ
Aesthet Surg J; 2023 Nov; 43(Suppl 1):S1-S9. PubMed ID: 36095026
[TBL] [Abstract][Full Text] [Related]
3. Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A.
Solish N; Carruthers J; Kaufman J; Rubio RG; Gross TM; Gallagher CJ
Drugs; 2021 Dec; 81(18):2091-2101. PubMed ID: 34787840
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines.
Humphrey S; Dover JS; Bowsher RR; Clancy A; Liu Y; Prawdzik G; Gallagher CJ
Aesthet Surg J; 2023 Sep; 43(10):1189-1193. PubMed ID: 37051886
[TBL] [Abstract][Full Text] [Related]
5. Impact of Glabellar Injection Technique With DaxibotulinumtoxinA for Injection on Brow Position.
Bertucci V; Green JB; Fezza JP; Brown J; Gallagher CJ; Solish N
Aesthet Surg J; 2023 Nov; 43(Suppl 1):S10-S18. PubMed ID: 36322141
[TBL] [Abstract][Full Text] [Related]
6. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Results from Each of Two Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Studies (SAKURA 1 and SAKURA 2).
Carruthers JD; Fagien S; Joseph JH; Humphrey SD; Biesman BS; Gallagher CJ; Liu Y; Rubio RG; ;
Plast Reconstr Surg; 2020 Jan; 145(1):45-58. PubMed ID: 31609882
[TBL] [Abstract][Full Text] [Related]
7. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: Pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2).
Bertucci V; Solish N; Kaufman-Janette J; Yoelin S; Shamban A; Schlessinger J; Snyder D; Gallagher C; Liu Y; Shears G; Rubio RG
J Am Acad Dermatol; 2020 Apr; 82(4):838-845. PubMed ID: 31791824
[TBL] [Abstract][Full Text] [Related]
8. Clinical Immunogenicity of DaxibotulinumtoxinA for Injection in Glabellar Lines: Pooled Data from the SAKURA Phase 3 Trials.
Gallagher CJ; Bowsher RR; Clancy A; Dover JS; Humphrey S; Liu Y; Prawdzik G
Toxins (Basel); 2023 Jan; 15(1):. PubMed ID: 36668880
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial.
Comella CL; Jankovic J; Hauser RA; Patel AT; Banach MD; Ehler E; Vitarella D; Rubio RG; Gross TM;
Neurology; 2024 Feb; 102(4):e208091. PubMed ID: 38295339
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of DaxibotulinumtoxinA for Injection in the Treatment of Glabellar Lines by Age and Race: Subgroup Analysis of the SAKURA Clinical Trials.
Solish N; Burgess CM; Weinkle SH; Ablon G; Brown J; Kooken K; Rubio RG
Aesthet Surg J; 2023 Feb; 43(2):205-214. PubMed ID: 36087303
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Upper Facial Lines With DaxibotulinumtoxinA for Injection: Results From an Open-Label Phase 2 Study.
Dover JS; Humphrey SD; Lorenc ZP; Shamban A; Gross TM; Rubio RG; Vitarella D
Dermatol Surg; 2023 Jan; 49(1):60-65. PubMed ID: 36533798
[TBL] [Abstract][Full Text] [Related]
12. Biochemical Stability and Microbial Control of Reconstituted DaxibotulinumtoxinA-lanm for Injection.
Ellis K; Thach T; Gallagher CJ
Toxins (Basel); 2023 Dec; 15(12):. PubMed ID: 38133187
[TBL] [Abstract][Full Text] [Related]
13. Bridging the Gap: Sustained Treatment Effect of Glabellar Lines With Twice-A-Year Treatment With DaxibotulinumtoxinA.
Dover JS; Solish N; Gross TM; Gallagher CJ; Brown J
Dermatol Surg; 2023 Sep; 49(9):862-864. PubMed ID: 37384899
[TBL] [Abstract][Full Text] [Related]
14. Progressive Improvement in Static Glabellar Lines After Repeated Treatment With DaxibotulinumtoxinA for Injection.
Glogau R; Kontis TC; Liu Y; Gallagher CJ
Dermatol Surg; 2021 Dec; 47(12):1579-1584. PubMed ID: 34417396
[TBL] [Abstract][Full Text] [Related]
15. DaxibotulinumtoxinA for Injection for the Treatment of Glabellar Lines: Efficacy Results From SAKURA 3, a Large, Open-Label, Phase 3 Safety Study.
Fabi SG; Cohen JL; Green LJ; Dhawan S; Kontis TC; Baumann L; Gross TM; Gallagher CJ; Brown J; Rubio RG
Dermatol Surg; 2021 Jan; 47(1):48-54. PubMed ID: 32773446
[TBL] [Abstract][Full Text] [Related]
16. A 3D Morphometrical Evaluation of Brow Position After Standardized Botulinum Toxin A Treatment of the Forehead and Glabella.
Schlager S; Kostunov J; Henn D; Stark BG; Iblher N
Aesthet Surg J; 2019 Apr; 39(5):553-564. PubMed ID: 30124769
[TBL] [Abstract][Full Text] [Related]
17. DaxibotulinumtoxinA-lanm (Daxxify™): A Comprehensive Overview.
Salame N; Eber AE; Dover J
Skin Therapy Lett; 2023 Jul; 28(4):1-3. PubMed ID: 37440610
[TBL] [Abstract][Full Text] [Related]
18. Dynamic Evaluation of Skin Displacement by the Frontalis Muscle Contraction Using Three-Dimensional Skin Displacement Vector Analysis.
Kwon IJ; Lee W; Moon HJ; Lee SE
Yonsei Med J; 2023 Jul; 64(7):440-447. PubMed ID: 37365738
[TBL] [Abstract][Full Text] [Related]
19. Anatomical Proposal for Botulinum Neurotoxin Injection for Horizontal Forehead Lines.
Yi KH; Lee JH; Seo KK; Kim HJ
Plast Reconstr Surg; 2024 Feb; 153(2):322e-325e. PubMed ID: 36988646
[TBL] [Abstract][Full Text] [Related]
20. Prior Botulinum Toxin Treatment Does Not Impact Efficacy or Safety in Clinical Trials: Analysis of DaxibotulinumtoxinA for Injection in the SAKURA Program.
Cohen JL; Green LJ; Beer KR; Liu Y; Gallagher CJ
Dermatol Surg; 2021 Apr; 47(4):511-515. PubMed ID: 33587381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
